Turning high-throughput structural biology into predictive inhibitor design

Turning high-throughput structural biology into predictive inhibitor design

A common challenge in drug design pertains to finding chemical modifications to a ligand that increases its affinity to the target protein. An underutilized advance is the increase in structural biology throughput, which has progressed from an artisanal endeavor to a monthly throughput of hundreds o...

詳細記述

書誌詳細
主要な著者: Saar, KL, McCorkindale, W, Fearon, D, Boby, M, Barr, H, Ben-Shmuel, A, London, N, von Delft, F, Chodera, JD, Lee, AA, Koekemoer, L, Krojer, T, Fairhead, M, MacLean, EM, Thompson, A, Smilova, MD, Wright, N, von Delft, A, Gileadi, C, Schofield, CJ, Salah, E, Malla, TR, Tumber, A, John, T, Vakonakis, I, Kantsadi, AL, Zitzmann, N, Brun, J, Kiappes, JL, Hill, M, Witt, KD, Alonzi, DS, Makower, LL, Giroud, C, Bennett, J, Fedorov, O, Morris, GM, Ferla, M, Carbery, A, Cattermole, E, Taylor, JC, Brewitz, L
その他の著者: COVID Moonshot Consortium
フォーマット: Journal article
言語:English
出版事項: National Academy of Sciences 2023

類似資料